Hormone replacement therapy has been a controversial treatment for the last three decades, with different studies claiming complex benefits and risks associated with women taking HRT. Currently, there are about 12 million users of HRT globally, including approximately one million in the UK.
This new analysis, published in The Lancet, brings together and assesses the main epidemiological evidence on the association between different types of HRT and the incidence of breast cancer since 1992. The study also looks at the effects of different types of HRT and the long-term risks after women have stopped using HRT.
Journalists came to the SMC to hear the study authors discuss:
Prof Valerie Beral, Professor of Epidemiology and Director of Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford.
Prof Gillian Reeves, Professor of Statistical Epidemiology, Nuffield Department of Population Health, University of Oxford.
Prof Richard Peto, Professor of Medical Statistics & Epidemiology and Co-Director of the Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford. (TBC)
This Briefing was accompanied by an SMC Round Up.